On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.
It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more.
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes.
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.
The Supreme Court’s much-anticipated Prometheus decision has prompted strong reactions among IP practitioners, as MaryAnne Armstrong, PhD, explains.
The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.
BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future.